PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW128009View Pathway |
drug action
Rivastigmine Action PathwayHomo sapiens
Rivastigmine is a cholinesterase inhibitor used in the treatment of symptoms of dementia in Alzheimer's and Parkinson's. The drug reversible binds to and inhibits acetylcholinesterase and cholinesterase which stops the breakdown of acetylcholine which increases the concentration in the synaptic cleft. It is metabolized by the enzymes it inhibits and forms the metabolite NAP226-90.
|
Creator: Selena Created On: June 29, 2023 at 09:31 Last Updated: June 29, 2023 at 09:31 |
PW128292View Pathway |
drug action
Rivastigmine Action Pathway (new)Homo sapiens
Rivastigmine is a cholinesterase inhibitor used in the treatment of symptoms of dementia in Alzheimer's and Parkinson's. The drug reversible binds to and inhibits acetylcholinesterase and cholinesterase which stops the breakdown of acetylcholine which increases the concentration in the synaptic cleft. It is metabolized by the enzymes it inhibits and forms the metabolite NAP226-90.
|
Creator: Selena Created On: August 15, 2023 at 18:47 Last Updated: August 15, 2023 at 18:47 |
PW145087View Pathway |
drug action
Rivastigmine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:03 Last Updated: October 07, 2023 at 15:03 |
PW176230View Pathway |
Rivastigmine Predicted Metabolism PathwayHomo sapiens
Metabolites of Rivastigmine are predicted with biotransformer.
|
Creator: Omolola Created On: December 04, 2023 at 12:58 Last Updated: December 04, 2023 at 12:58 |
PW145052View Pathway |
drug action
Rizatriptan Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:59 Last Updated: October 07, 2023 at 14:59 |
PW128616View Pathway |
drug action
Rizatriptan Mechanism of Action Action PathwayHomo sapiens
Rizatriptan is a triptan used to treat migraines with or without aura. Rizatriptan is a second-generation triptan and a selective 5-HT1B and 5-HT1D receptor agonist. Rizatriptan is not indicated for the prophylactic therapy of migraine nor the treatment of cluster headache. Rizatriptan has a weak affinity for other 5-HT1 receptor subtypes (5-HT1A, 5-HT1E, 5-HT1F) and the 5-HT7 receptor but has no significant activity at 5-HT2, 5-HT3, alpha- and beta-adrenergic, dopaminergic, histaminergic, muscarinic or benzodiazepine receptors. Rizatriptan is a selective agonist at the 5-HT1B and 5-HT1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system. It binds to these receptors with high affinity. The exact mechanism of action of rizatriptan has not been fully elucidated; however, several documented pharmacological actions of rizatriptan may contribute to its antimigraine effects. Rizatriptan causes vasoconstriction of intracranial extracerebral blood vessels, which is thought to occur primarily via 5-HT1B receptors. Rizatriptan also inhibits nociceptive neurotransmission in trigeminal pain pathways. It attenuates the release of vasoactive neuropeptides by the trigeminal nerve, which is thought to occur via neurogenic and central 5-HT1D receptors. Rizatriptan inhibited neurogenic dural vasodilation and plasma protein extravasation in animal studies.
|
Creator: Omolola Created On: September 06, 2023 at 16:32 Last Updated: September 06, 2023 at 16:32 |
PW123685View Pathway |
RL TestPseudomonas aeruginosa
Rhamnolipids (RL) consist of a fatty acyl moiety composed of a 3-(3-hydroxyalkanoyloxy)alkaloid acid (HAA) and a sugar moiety composed of one or two rhamnose sugars. Rhamnolipids function as surfactants and virulence factors and are involved in biofilm formation and cell motility. The rhamnose sugar component is produced via the dTDP-L-rhamnose biosynthetic pathway which forms dTDP-L-rhamnose from glucose 6-phosphate (G6P) in five steps. First, glucose 6-phosphate is converted into glucose 1-phosphate (G1P) via the enzyme phosphoglucomutase (AlgC). Second, glucose 1-phosphate is converted into dTDP-D-glucose via the enzyme glucose-1-phosphate thymidylyltransferase (RmlA). Third, dTDP-D-glucose is converted into dTDP-4-dehydro-6-deoxy-D-glucose via the enzyme dTDP-glucose 4,6-dehydratase (RmlB). Fourth, dTDP-4-dehydro-6-deoxy-D-glucose is converted into dTDP-4-dehydro-L-rhamnose via the enzyme dTDP-4-dehydrorhamnose 3,5-epimerase (RmlC). Fifth, dTDP-4-dehydro-L-rhamnose is converted into dTDP-L-rhamnose via the enzyme dTDP-4-dehydrorhamnose reductase (RmlD). The HAA component is synthesized from 3-hydroxyacyl-[acyl-carrier protein] diverted from fatty acid biosynthesis via the enzyme 3-(3-hydroxydecanoyloxy)decanoate synthase (RhIA). The final step in rhamnolipid biosynthesis is the formation of the glycosidic link between the rhamnose sugar component and the HAA component. This is accomplished by two rhamnosyltransferases (RhlB and RhlC) which catalyze sequential glycosyl transfer reactions to first form mono-rhamnolipids (via RhIB) and then di-rhamnolipids (via RhIC). RHlA, RHlB, and RHlC are associated with the inner membrane.
|
Creator: Carin Li Created On: January 17, 2020 at 10:59 Last Updated: January 17, 2020 at 10:59 |
PW064732View Pathway |
RNAiHomo sapiens
|
Creator: Guest: Anonymous Created On: May 02, 2018 at 09:44 Last Updated: May 02, 2018 at 09:44 |
PW144840View Pathway |
drug action
Rocuronium Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:32 Last Updated: October 07, 2023 at 14:32 |
PW176131View Pathway |
Rocuronium Predicted Metabolism Pathway newHomo sapiens
Metabolites of Rocuronium are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 14:11 Last Updated: November 29, 2023 at 14:11 |